Abstract
We address an unmet challenge in Parkinson’s disease: the lack of biomarkers to identify the right patients for the right therapy, which is a main reason clinical trials for disease modifying treatments have all failed. The gut microbiome is a new target for treatment of Parkinson’s disease, with potential to halt disease progression. Our aim was to develop microbiome-based biomarkers to guide patient selection for microbiome-based clinical trials. We used microbial taxa that have been robustly associated with Parkinson’s disease across studies and at high significance as dysbiotic features of Parkinson’s disease. Using individual-level taxonomic relative abundance data, we classified patients according to their dysbiotic features, effectively defining microbiome-based subtypes of PD. We show that not all persons with Parkinson’s disease have a dysbiotic microbiome, and not all dysbiotic Parkinson’s disease microbiomes have the same features. Grounded in robust and reproducible data from differential abundance studies, we propose an intuitive and easily modifiable method to identify the optimal candidates for microbiome-based clinical trials, and subsequently, for treatments that are personalized for each individual’s dysbiotic features. We demonstrate the method for Parkinson’s disease. The concept, and the method, is generalizable for any disease with a microbiome component.
Competing Interest Statement
HP has intellectual property pending on Personalized Microbiome-Based Therapies, Serial No.: 63/571,787; Filing Date: March 29, 2024. TRS is a co-inventor on intellectual property related to a small molecule microbiome-based therapy - US Patent 11,707,493 and 11,147, 792.
Funding Statement
This work was supported by The Strain Endowed Chair in Parkinson's Disease to the University of Alabama at Birmingham (HP) and Aligning Science Across Parkinson's (ASAP-020527) through the Michael J. Fox Foundation for Parkinson's Research (MJFF) (HP, TRS, CFM). For the purpose of open access, the authors have applied a CC BY public copyright license to all Author Accepted Manuscripts arising from this submission. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally published in Nat Comm (https://www.nature.com/articles/s41467-022-34667-x). The raw metagenomic sequences and accompanying metadata are located at the NCBI SRA under BioProject ID PRJNA834801 (https://www.ncbi.nlm.nih.gov/bioproject/834801), and post-QC and post taxonomic profiling data are on Zenodo (https://zenodo.org/record/7246185).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The revision was made to (1) clarify that this is not a method for discovering disease associated features, in fact, having well-established disease-associated features are a requisite (2) to fulfill funding agency requirements on open access (3) include Zach Wallen as co-author.
Data availability
The dataset used for biomarker development is publicly available, open access with no restrictions, as described in detail in Wallen et al 2022 9. The dataset is available on two repositories to enable the investigators to download the data in either the raw or processed form. The raw metagenomic sequences and accompanying metadata are on NCBI SRA under BioProject ID PRJNA834801 [https://www.ncbi.nlm.nih.gov/bioproject/834801]. The post-QC and post taxonomic profiling data are on Zenodo [https://zenodo.org/record/7246185]. Here we used species-level data (presented in Supplement) that was extracted from the taxonomic profiling data downloaded from Zenodo in January 2024.
